Institutional Ownership
Allogene Therapeutics Inc
CUSIP 019770106COMALLOQ1 2026
13D / 13G Filings
52
Schedule 13D/13G on record
Beneficial Filers
20
Distinct reporting persons
Largest Stake
17.1%
Max % of class reported
Institutional Holders
203
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
52 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Arie Belldegrun, M.D. | 13G/A | 5.8% | 13.25M | SEC |
| 2 | Feb 13, 2026 | David D. Chang, M.D., Ph.D. | 13G | 5.2% | 12.10M | SEC |
| 3 | Feb 13, 2026 | Pfizer Inc. | 13D/A | 9.0% | — | SEC |
| 4 | Nov 13, 2025 | Capital World Investors | 13G/A | — | — | SEC |
| 5 | Nov 13, 2025 | Arie Belldegrun, M.D. | 13G/A | 5.6% | 12.67M | SEC |
| 6 | Nov 12, 2025 | David D. Chang, M.D., Ph.D. | 13G/A | 4.9% | 11.23M | SEC |
| 7 | Aug 12, 2025 | Arie Belldegrun, M.D. | 13G/A | 5.7% | 12.61M | SEC |
| 8 | Aug 8, 2025 | David D. Chang, M.D., Ph.D. | 13G/A | 5.0% | 11.14M | SEC |
| 9 | Jul 16, 2025 | Citadel Advisors LLC | 13G | 6.1% | 13.35M | SEC |
| 10 | May 13, 2025 | Capital World Investors | 13G | 5.6% | 12.27M | SEC |
42 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Allogene Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Pfizer Inc | 22.03M | $49.79M |
| 2 | Blackrock, Inc. | 19.09M | $46.58M |
| 3 | Tpg Gp A, LLC | 18.72M | $45.67M |
| 4 | State Street Corp | 8.66M | $21.13M |
| 5 | Primecap Management Co/Ca/ | 8.38M | $20.45M |
| 6 | Citadel Advisors LLC | 6.79M | $16.58M |
| 7 | Two Sigma Investments, LP | 5.38M | $13.12M |
| 8 | Geode Capital Management, LLC | 4.12M | $10.07M |
| 9 | Frazier Life Sciences Management, L.P. | 3.80M | $9.26M |
| 10 | Woodline Partners LP | 3.50M | $8.54M |